Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-07-18

FDA Approved: OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE — Original Application (Macleods Pharmaceuticals Limited)

View source ↗

Summary

FDA approves the generic fixed-dose combination of olmesartan medoxomil, amlodipine, and hydrochlorothiazide for hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Olmesartan medoxomil amlodipine and hydrochlorothiazide (olmesartan medoxomil; amlodipine; hydrochlorothiazide)

Snippet

ORIG AP for OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE (OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE)